Sign In
Buy MITO
$0.320
+0 (+0%)
At Close: Feb 14, 2023
Stealth BioTherapeutics to Present at Upcoming September Virtual Investor Conferences
04:30pm, Tuesday, 07'th Sep 2021
BOSTON, Sept. 7, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapie
Stealth (MITO) Files NDA for Ultra-Rare Disease Candidate
01:06pm, Wednesday, 25'th Aug 2021
Stealth BioTherapeutics (MITO) files a new drug application for elamipretide to the FDA for the treatment of Barth syndrome, an ultra-rare genetic condition.
Stealth Bio Files US Application For Ultra Rare Genetic Disease Candidate
09:29am, Tuesday, 24'th Aug 2021
Stealth BioTherapeutics Corp (NASDAQ: MITO) has submitted an elamipretide marketing application to the FDA for Barth syndrome. The submission is based on results from the SPIBA-001 Phase 3 Retrospe
Stealth BioTherapeutics Submits Elamipretide New Drug Application to FDA for Treatment of Barth Syndrome
07:30am, Tuesday, 24'th Aug 2021
BOSTON, Aug. 24, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapie
Stealth BioTherapeutics Strengthens IP Portfolio with Issuance of U.S. Patents Covering Elamipretide for Barth Syndrome
07:30am, Monday, 23'rd Aug 2021
BOSTON, Aug. 23, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapie
Stealth BioTherapeutics to Present at H.C. Wainwright Ophthalmology Virtual Healthcare Conference
07:30am, Wednesday, 11'th Aug 2021
BOSTON, Aug. 11, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapie
Stealth BioTherapeutics Corp (MITO) CEO Irene McCarthy on Q2 2021 Results - Earnings Call Transcript
04:25pm, Saturday, 07'th Aug 2021
Stealth BioTherapeutics Corp (MITO) CEO Irene McCarthy on Q2 2021 Results - Earnings Call Transcript
Stealth BioTherapeutics Reports Second Quarter 2021 Financial Results And Recent Business Highlights
07:30am, Thursday, 05'th Aug 2021
BOSTON, Aug. 5, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies
Stealth BioTherapeutics to Report Second Quarter Financial Results on Thursday, August 5
04:30pm, Friday, 30'th Jul 2021
BOSTON, July 30, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies
Stealth BioTherapeutics (MITO) Sees Hammer Chart Pattern: Time to Buy?
06:46am, Thursday, 08'th Jul 2021
Stealth BioTherapeutics (MITO) has been struggling lately, but the selling pressure may be coming to an end soon.
Stealth BioTherapeutics Joins the Rare Disease Company Coalition
04:30pm, Wednesday, 07'th Jul 2021
BOSTON, July 7, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies
Stealth BioTherapeutics Stock Surges On Elamipretide's European Orphan Drug Tag for Ultra-Rare Genetic Condition
07:08am, Wednesday, 02'nd Jun 2021
The European Medicines Agency (EMA) has granted orphan drug designation to Stealth BioTherapeutics Corp's (NASDAQ: MITO) elamipretide for Barth syndrome, an ultra-rare genetic condition. Barth syn
BOSTON, June 1, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies
Stealth BioTherapeutics to Present at Jefferies Virtual Healthcare Conference
07:30am, Friday, 28'th May 2021
BOSTON, May 28, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies
Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q1 2021 Results - Earnings Call Transcript
12:15pm, Tuesday, 18'th May 2021
Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q1 2021 Results - Earnings Call Transcript
